AstraZeneca plans to delist from Nasdaq and move to the NYSE, while its breast cancer drug Enhertu enters European regulatory ...

We recently compiled a list of the Top 10 Oncology Stocks to Buy Now. AstraZeneca PLC is placed fourth on our list among the ...

January 2026 AstraZeneca to complete direct listing of ordinary shares and all US debt securities on the New York Stock ExchangeTicker symbol for ordinary shares will remain AZN AstraZeneca PLC ("Astr ...

Oakmark Funds, advised by Harris Associates, released its “Oakmark International Fund” fourth-quarter 2025 investor letter.

AstraZeneca (NASDAQ:AZN) used its presentation at the J.P. Morgan Healthcare Conference to highlight strong 2025 performance, ...

AstraZeneca PLC ADR stock grades by Barron's. View AZN fundamental and sentiment analysis powered by MarketGrader.

AstraZeneca PLC AZN shares rallied 4.89% to £140.38 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the FTSE 100 Index UKX rising 1.18% to 10,122.73.

AstraZeneca PLC (NASDAQ:AZN) is one of the best performing pharma stocks in 2025. On January 7, Berenberg Bank reiterated a ...

AstraZeneca PLC ("AstraZeneca") today provided notice of the voluntary withdrawal from listing on The Nasdaq Stock Market LLC ("Nasdaq") of (i) its ...

(Alliance News) - Daiichi Sanyko Co Ltd on Monday said EU regulators had validated an application for its breast cancer treatment, Enhertu with pertuzumab, jointly developed with AstraZeneca PLC. This ...

AstraZeneca PLC ADR closed 6.81% short of its 52-week high of $96.51, which the company achieved on January 7th.

Welcome to the award-winning Money Distilled newsletter. I’m John Stepek. Every week day I look at the biggest stories in markets and economics, and explain what it all means for your money.